Phase II
Hutchison China MediTech Limited has initiated an international Phase I/Ib study of HMPL-689, its novel, highly selective and potent small molecule phosphoinositide-3 kinase delta isoform inhibitor, in patients with relapsed or refractory lymphoma.
Akari Therapeutics, Plc announced financial results for the second quarter ended June 30, 2019 and recent clinical progress.
Esperion announced positive top-line results from the Phase 2 bempedoic acid / ezetimibe combination tablet study.
Santhera Pharmaceuticals announces publication by ReveraGen of positive study data with vamorolone in patients with Duchenne muscular dystrophy.
Biopharma companies large and small are involved in numerous clinical trials. Here’s a look at some of the top stories from last week.
“It’s important to recognize that this problem is there and this problem is persisting over the years,” Kanwal Raghav, author of the study and an oncologist at MD Anderson Cancer Center, told STAT.
As summer winds its way to an end, biopharmaceutical companies continue to conduct clinical trials and release news related to them. Here’s a look at last week’s clinical trial headlines.
Akari Therapeutics, plc announced new preclinical and human data demonstrating the potential benefits of the dual inhibition of complement (C5) and leukotriene (LTB4) pathways by nomacopan for the treatment of pemphigoid disease (PD).
Cytovation AS and Specialized Medical Services-oncology BV announce that SMS-oncology has been selected as the CRO to conduct the phase I/II clinical trial with CyPep-1 in patients with advanced solid cancers.
Last week was a particularly busy week for biopharma companies to release information about ongoing clinical trials. Here’s a look.
PRESS RELEASES